Recently, the **Clinical Practice Guidelines for Immune Checkpoint Inhibitors in Gynecologic Oncology (2025 Edition)** [1] were updated and released. Enlangsubai Monoclonal Antibody Injection (Enshuxing®), independently developed by CSPC Innovation, has been recommended in the guidelines for the **first-line treatment of recurrent or metastatic cervical cancer** and the **second-line treatment of recurrent or metastatic cervical cancer (regardless of PD-L1 expression status)**. Previously, Enlangsubai Monoclonal Antibody had already received **Class 2A recommendations** in: - *Chinese Clinical Practice Guidelines for Gynecologic Oncology (2024 Edition)* [2] - *Clinical Practice Guidelines for Immune Checkpoint Inhibitors in Cervical Cancer (2024 Edition)* [3] - *CSCO Guidelines for the Diagnosis and Treatment of Cervical Cancer (2024 Edition)* [4] Its inclusion in the *Clinical Practice Guidelines for Immune Checkpoint Inhibitors in Gynecologic Oncology (2025 Edition)* provides scientific clinical guidance for the clinical application of Enlangsubai Monoclonal Antibody.

Enlangsubai Monoclonal Antibody Injection is a Class 1 therapeutic biological product with invention patents and fully independent intellectual property rights. It was approved for marketing by the NMPA in June 2024 for the treatment of PD-L1‑positive (CPS ≥ 1) recurrent or metastatic cervical cancer that has failed prior platinum‑containing chemotherapy. In 2025, it was included in the 2024 National Reimbursement Drug List through national negotiated pricing.[5] This recommendation in authoritative guidelines serves as recognition and encouragement for CSPC Innovation’s R&D capabilities. The company will continue to advance clinical research in gynecologic oncology, bringing hope to more patients.